Evidence map›Paper›PMID 38288866›Full record

ArticleThe Laryngoscope2024

Characterization of a Diverse Set of Conditionally Reprogrammed Head and Neck Cancer Cell Cultures.

Thomas J Ow, Vikas Mehta, Daniel Li, Carlos Thomas, Nitisha Shrivastava, Nicole Kawachi, Adam J Gersten, Jing Zhu, Bradley A Schiff, Richard V Smith and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Laryngoscope, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Thomas J OwMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.ORCID 0000-0001-9389-2332
Vikas MehtaMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Daniel LiMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Carlos ThomasMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Nitisha ShrivastavaMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Nicole KawachiMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Adam J GerstenMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Jing ZhuMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Bradley A SchiffMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.ORCID 0000-0002-5860-3627
Richard V SmithMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.ORCID 0000-0002-5216-6374
Gregory RosenblattMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Stelby AugustineMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Michael B PrystowskyMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Shanye YinMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Evripidis GavathiotisMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Chandan GuhaMontefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Development of a genetic and molecular prediction model for cisplatin and radiation resistance in head and neck squamous cell carcinomaK23DE027425 · NIDCR · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI OW, THOMAS JULIAN · 2018 to 2020
$517k
NCI NIH HHS NIH-NCI P30CA013330NCI NIH HHS P30 CA013330NIDCR NIH HHS K23 DE027425
6 · The paper itself

Abstract

objectiveTo establish and characterize a diverse library of head and neck squamous cell cancer (HNSCC) cultures using conditional reprogramming (CR).

methodsPatients enrolled on an IRB-approved protocol to generate tumor cell cultures using CR methods. Tumor and blood samples were collected and clinical information was recorded. Successful CR cultures were validated against banked reference tumors with short tandem repeat genotyping. Cell morphology was archived with photodocumentation. Clinical and demographic factors were evaluated for associations with successful establishment of CR culture. Human papilloma virus (HPV) genotyping, clonogenic survival, MTT assays, spheroid growth, and whole exome sequencing were carried out in selected cultures.

resultsForty four patients were enrolled, with 31 (70%) successful CR cultures, 32% derived from patients who identified as Black and 61% as Hispanic. All major head and neck disease sites were represented, including 15 (48%) oral cavity and 8 (26%) p16-positive oropharynx cancers. Hispanic ethnicity and first primary tumors (vs. second primary or recurrent tumors) were significantly associated with successful CR culture. HPV expression was conserved in CR cultures, including CR-024, which carried a novel HPV-69 serotype. CR cultures were used to test cisplatin responses using MTT assays. Previous work has also demonstrated these models can be used to assess response to radiation and can be engrafted in mouse models. Whole exome sequencing demonstrated that CR cultures preserved tumor mutation burden and driver mutations.

conclusionCR culture is highly successful in propagating HNSCC cells. This study included a high proportion of patients from underrepresented minority groups. LEVEL OF EVIDENCE: Not Applicable Laryngoscope, 134:2748-2756, 2024.

Indexed as

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedCellular ReprogrammingCellular Reprogramming TechniquesExome SequencingFemaleHumansMaleMiddle AgedTumor Cells, Culturedcancer of head and neckcell culture techniquesdiversityequityhuman papillomavirusinclusiontranslational medical research

Identifiers

PMID38288866
PMCPMC12007172
OpenAlexW4391361085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.